Stem Cell Transplant

The Yale Transplant Advantage

Yale New Haven Hospital is a member of the National Marrow Donor Program and is accredited as a major transplant center by the FACT transplant accreditation committee.

In an effort to destroy abnormal cancerous cells in leukemia, lymphoma and multiple myeloma, stem cell transplants are often used. Yale is the only center in Connecticut offering allogeneic transplant, a transplant using compatible donor stem cells. 

New clinical trials are available for patients who have not been successfully matched with a donor and are at high risk for relapse. Available in only a handful of cancer centers in the country, Yale Cancer Center is currently performing:

  • Non-myeloablative or reduced intensity transplants, which is a technique that uses a less intense treatment to prepare a patient for transplant and alternatively relies on the donor's immune cells combined with newer agents to fight the cancer. Lead physician is Stuart Seropian, MD.

Stem cell allotransplantation can cause a side effect called graft-versus-host disease in 40-50% of patients who receive transplant. Yale Cancer Center researchers have long been considered leaders in developing novel techniques to eliminate this disease. Advances include:

  • The discovery that dendritic, or immune cells, are necessary in causing graft-versus-host disease. The deletion of T-cells from the donor stem cells removes the incidence of graft-versus-host but may also decrease the effectiveness of the transplant.
  • The introduction of intravenous infusions of autologous immature dendritic cells before an allogeneic transplant. 

The National Marrow Donor Program tracks data on patients who have received a transplant at accredited United States Transplant Centers. Smilow Cancer Hospital/Yale Cancer Center’s actual results are above the predicted survival range. Over 20,000 patients are transplanted in the United States per year. Learn More

The following chart shows how Yale Cancer Center compares to Transplant Centers in the United States Reporting More than 50 Allogeneic Transplants During the Last Reporting Period (2014 – 2015).

Institution

Number of Patients

One-Year Survival

Predicted Survival

Yale University/Yale New Haven Hospital

87

71.8%

63.1%

B

654

87.9%

76.0%

C

113

80.4%

72.2%

D

229

79.0%

63.3%

E

55

77.5%

62.8%

F

556

77.1%

65.8%

G

80

76.3%

66.7%

H

188

75.7%

62.2%

I

357

75.1%

63.8%

J

426

74.6%

68.8%

K

210

74.4%

68.8%

L

553

74.2%

67.1%

M

200    

73.3%

65.6%

N

100

73.1%

56.4%

O

82

72.7%

60.9%

P

112

72.6%

52.9%

Q

76

72.0%

56.3%

R

93

71.2%

59.8%

S

69

71.0%

64.4%

T

366

70.4%

63.8%

U

333

70.3%

66.7%

V

118

70.0%

66.4%

W

268

68.2%

64.9%

X

128

68.1%

62.8%

Y

96

67.8%

65.8%

Z

167

67.2%

58.7%

AA

103

67.1%

61.5%

BB

267

66.4%

59.7%

CC

226

66.0%

57.3%

DD

158

64.7%

61.7%

EE

55

64.6%

52.5%

FF

147

64.1%

57.3%

GG

719

63.2%

61.4%

HH

224

63.0%

59.9%

II

159

62.9%

57.4%

JJ

242

62.6%

63.4%

KK

169

62.5%

65.4%

LL

245

62.0%

58.8%

MM

65

61.9%

63.7%

NN

169

62.5%

65.4%

OO

245

62.0%

58.8%

PP

65

61.9%

56.5%

QQ

169

61.9%

65.4%

RR

344

61.3%

63.3%

SS

81

59.4%

58.9%

TT

108

59.2%

60.8%

UU

101

58.6%

58.3%

VV

60

57.3%

57.5%

WW

465

56.0%

57.5%

XX 77 50.0% 51.1%